US20090014395A1 - Systems and Methods for On Line Finishing of Cellular Blood Products Like Platelets Harvested for Therapeutic Purposes - Google Patents
Systems and Methods for On Line Finishing of Cellular Blood Products Like Platelets Harvested for Therapeutic Purposes Download PDFInfo
- Publication number
- US20090014395A1 US20090014395A1 US12/179,658 US17965808A US2009014395A1 US 20090014395 A1 US20090014395 A1 US 20090014395A1 US 17965808 A US17965808 A US 17965808A US 2009014395 A1 US2009014395 A1 US 2009014395A1
- Authority
- US
- United States
- Prior art keywords
- blood
- container
- systems
- leukocytes
- finishing device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 239000010836 blood and blood product Substances 0.000 title description 2
- 229940125691 blood product Drugs 0.000 title description 2
- 230000001413 cellular effect Effects 0.000 title 1
- 210000004369 blood Anatomy 0.000 claims abstract description 65
- 239000008280 blood Substances 0.000 claims abstract description 65
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 46
- 238000004891 communication Methods 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims description 27
- 230000007774 longterm Effects 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims 8
- 239000006285 cell suspension Substances 0.000 claims 8
- 238000005086 pumping Methods 0.000 claims 3
- 238000003672 processing method Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 22
- 210000001772 blood platelet Anatomy 0.000 description 51
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 17
- 210000004623 platelet-rich plasma Anatomy 0.000 description 13
- 239000000306 component Substances 0.000 description 11
- 239000000835 fiber Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003634 thrombocyte concentrate Substances 0.000 description 5
- 239000012503 blood component Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- KRADHMIOFJQKEZ-UHFFFAOYSA-N Tri-2-ethylhexyl trimellitate Chemical compound CCCCC(CC)COC(=O)C1=CC=C(C(=O)OCC(CC)CCCC)C(C(=O)OCC(CC)CCCC)=C1 KRADHMIOFJQKEZ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
Definitions
- the invention generally relates to blood processing systems and methods. In a more specific sense, the invention relates to systems and methods for removing leukocytes from blood components collected for therapeutic purposes.
- Today blood collection facilities routinely separate whole blood into its various therapeutic components, such as red blood cells, platelets, and plasma.
- the bag system includes a primary blood bag and one or more transfer bags, which are integrally connected to the primary bag by tubing.
- the technique collects from a donor a single unit (about 450 ml) of whole blood in the primary blood bag. The donor is then free to leave.
- the plasma rich in platelets is expressed out of the primary bag into a transfer bag, leaving the red blood cells behind.
- the plasma rich in platelets then undergoes further centrifugal separation within the transfer bag into a concentration of platelets and plasma poor in platelets.
- the plasma poor in platelets is expressed from the transfer bag into another transfer bag, leaving the concentration of platelets behind.
- Certain therapies transfuse large volumes of a single blood component. For example, some patients undergoing chemotherapy require the transfusion of large numbers of platelets on a routine basis. Multiple blood bag systems simply are not an efficient way to collect these large numbers of platelets from individual donors.
- On line blood separation systems are today used to collect large numbers of platelets to meet this demand.
- On line systems perform the separation steps necessary to separate concentration of platelets from whole blood in a sequential process with the donor present.
- On line systems establish a flow of whole blood from the donor, separate out the desired platelets from the flow, and return the remaining red blood cells and plasma to the donor, all in a sequential flow loop.
- U.S. Pat. No. 5,427,695 is directed to the removal of leukocytes from platelet-rich plasma during on line blood processing.
- the platelet-rich suspension product obtained using prior on line blood collection systems and methods may still lack the desired physiologic characteristics imposed by the end user (typically a blood bank or hospital) for long term storage and transfusion.
- the platelet-rich suspension may include residual leukocytes that, while very small in relation to the leukocyte population in whole blood, are still greater than the leukocyte population standards desired by the end user.
- the invention provides on line blood processing systems and methods for obtaining a finished platelet suspension having a desired physiologic characteristic.
- the desired physiologic characteristic comprises a desired reduced residual population of leukocytes.
- the systems and methods that embody features of the invention establish on line communication between a container and a source of blood containing leukocytes and platelets, such as a human donor.
- the systems and methods create a centrifugal field between the source of blood and the container.
- the centrifugal field separates from the blood an unfinished suspension of platelets having a first physiologic characteristic different than the desired physiologic characteristic.
- the unfinished platelet suspension contains an initial leukocyte population greater than the desired residual leukocyte population.
- the systems and methods pump the unfinished platelet suspension outside the centrifugal field through a finishing device.
- the finishing device changes the first physiologic characteristic to the desired physiological characteristic, thereby creating the finished platelet suspension.
- the finishing device reduces the leukocyte population by filtration.
- the systems and methods convey the finished platelet suspension from the finishing device directly into the container for storage or transfusion.
- FIG. 1 is a diagrammatic view of a blood processing system, which includes a finishing device that embodies the features of the invention.
- FIG. 2 is a diagrammatic view of a centrifugal blood processing system that can be use in association with the finishing device shown in FIG. 1 .
- FIG. 1 shows in diagrammatic form an on line blood processing system 10 that embodies features of the invention.
- the on line system 10 provides a finished, high quality platelet-rich blood product (PLT FIN ), with a significantly reduced residual population of leukocytes and/or other enhanced physiological properties, suited for long term storage and transfusion.
- PKT FIN platelet-rich blood product
- the term “on line blood separation process” refers to a blood separation system or method that (i) establishes communication between a blood source (typically, a human blood donor) and an extracorporeal flow path; (ii) draws a blood volume from the donor into the flow path; and (iii) maintains communication with the circulatory system of the donor for at least a portion of the time that the blood volume undergoes separation within the extracorporeal flow path.
- a blood source typically, a human blood donor
- an “on line blood separation process” can separate the blood volume either in a continuous manner or in an interrupted manner. However, an “on line blood separation process” maintains communication between the flow path and the donor for at least a portion of the time the separation process occurs within the flow path, regardless of specific timing or sequencing of the separation process itself.
- an “on line blood separation process” can include external or internal valves or clamps to interrupt flow within the path to or from the donor.
- valves or claims do not break the communication between the blood donor and the flow path. Instead, the valves or clamps control fluid flow within the path while maintaining communication between it and the blood donor.
- the on line system 10 draws whole blood (WB) from a donor through a phlebotomized tubing flow path 12 .
- WB contains, as its principal components, red blood cells, platelets, leukocytes, and plasma.
- the system 10 adds anticoagulant to the drawn WB and conveys anticoagulated WB into a centrifugal field 14 for processing.
- the system 10 In the centrifugal field 14 , the system 10 ultimately separates anticoagulated WB into two components.
- the first component is a red blood cell concentration. It is desirable that the red blood cell concentration also carry with it a majority of the leukocyte population (LK) present in the WB. For this reason, the first component is referred to as RBC LK+ .
- RBC LK+ is returned to the donor during processing. This avoids depletion of the donor's red blood cell and leukocyte populations while high volume yields of platelets are obtained.
- the second component comprises an unfinished platelet-rich plasma suspension PLT UN .
- PLT UN is considered “unfinished” because the platelet-rich plasma suspension still lacks the desired physiologic characteristics imposed by the end user (typically a blood bank or hospital) for long term storage and transfusion. Centrifugal processing within the field 14 often cannot provide these desired characteristics.
- the specific physical makeup of the platelet-rich suspension comprising PLT UN can vary. The makeup will largely depend upon the efficiency of the centrifugal separation process in terms of the how many platelets are separated (i.e., the platelet yields) and how much platelet-poor plasma product is withdrawn and not returned to the donor.
- PLT UN is intended to encompass any suspension in which platelets are present in concentrations greater than in whole blood.
- PLT UN can comprise what is commonly referred to as platelet-rich plasma (PRP) or platelet concentrate (PC), or suspensions of platelets and plasma lying in between.
- PRP platelet-rich plasma
- PC platelet concentrate
- PLT UN can include, in addition to platelets, other components or ingredients, depending upon the choice of the end user.
- PLT UN can include essentially only plasma as the platelet suspension media.
- PLT UN can include a specially formulated platelet storage media to suspend the platelets.
- the structural details of the centrifugation field 14 can vary and are not essential to the invention.
- the field 14 can comprise a centrifuge and multiple stage centrifugal processing chambers of the type shown in Brown U.S. Pat. No. 5,427,695 or Brown U.S. Pat. No. 5,370,802, both of which are incorporated herein by reference.
- FIG. 2 shows in diagrammatic form, the multiple stage processing chambers that Brown '695 and '802 embody separate WB into RBC and PRP in a first stage separation chamber 16 .
- the special fluid flow dynamics that occur in the first stage chamber 16 shown in Brown '802 or '695 keep a large majority of leukocytes out of PRP and with the RBC in the first stage chamber 16 for return to the donor as RBC LK+ .
- the special fluid flow dynamics occurring in the first stage chamber 16 in Brown '802 or Brown '695 also provide a high yield of platelets in the PRP.
- PRP platelet-poor plasma
- PC retained in the second stage chamber 18 is later resuspended in a volume of PPP or (optionally) a suitable platelet storage medium for transfer from the second stage chamber as PLT UN .
- a portion of the PPP is returned to the donor, while another portion of PPP is retained for use as a recirculation or keep-open or rinse-back or resuspension media, or for storage for fractionation or transfusion.
- PLT UN can be considered “unfinished” in the context of the above described system is the presence of residual leukocytes in the platelet suspension. This residual population of leukocytes with the platelets, while small, still can be greater than the leukocyte population standards demanded by the end user.
- centrifugal processing alone often is not effective at isolating enough leukocytes from PRP to meet these demands.
- Unintended perturbations and secondary flows along the interface between RBC and plasma, where leukocytes reside can sweep lighter leukocyte species away from RBC into the plasma.
- Other desirable flow patterns that sweep heavier leukocytes species in the interface back into the RBC mass can also fail to develop to their fullest potential.
- the dynamic processes under which leukocytes are separated from platelets during centrifugation are complex and subject to variation from donor to donor.
- a leukocyte filter 20 can be provided after the first stage chamber 16 to filter leukocytes from PRP before entering the second stage chamber 18 for separation into PC and PPP.
- the filter 20 is preferably located outside the centrifugal field 14 , being connected by a rotating umbilicus arrangement 22 of conventional construction. Alternatively, though, the filter 20 can be located within the centrifugal field 14 .
- PLT UN can be subject to particle bed separation effects within the centrifugal field 14 to separate leukocytes from the platelets. Still, the degree of leukocyte reduction demanded by the user can exceed the capabilities of even these ancillary steps during the centrifugal separation process.
- the system 10 includes an in line finishing device 24 located outside the centrifugal field 14 .
- a pump 26 conveys PLT UN under pressure from the centrifugal field 14 through the finishing device 24 .
- the pump 26 is shown downstream of the centrifugal field 14 .
- the pump 26 could be located upstream of the centrifugal field 14 , thereby supplying the requisite machine pressure to convey PLT UN from the centrifugal field 14 .
- the finishing device 24 serves to affect a desired alteration in the makeup or physiological of PLT UN that could not be effectively achieved in the centrifugal field 14 , such as, for example, a further incremental reduction in the leukocyte population.
- the in line finishing device 24 performs its function on line, while the donor remains connected in communication with the system 10 .
- the output of the finishing device 24 is a finished platelet-rich suspension (PLT FIN ).
- PLT FIN is considered “finished” because the platelet-rich plasma suspension possesses the desired physiologic characteristics imposed by the end user for long term storage and transfusion.
- the platelet-rich suspension comprising PLT FIN possesses a more-reduced leukocyte population and/or additional physiological attributes not present in PLT INI .
- the term “reduced” or “more-reduced” does not denote that all the residual leukocytes have been removed.
- the term is intended to more broadly indicate only that the number of residual leukocytes have been incrementally reduced by the finishing device 24 , compared with the number before processing by the finishing device.
- finishing device can provide other physiological attributes.
- Other physiological attributes that the finishing device can provide include (INSERT . . . . )
- the finishing device 24 can accomplish its function by centrifugation, absorption, columns, chemical, electrical, and electromagnetic means.
- the finishing device 24 comprises a filter that employs a non-woven, fibrous filter media 28 .
- the composition of the filter media 28 can vary.
- the media 28 comprises fibers that contain nonionic hydrophillic groups and nitrogen-containing basic functional groups. Fibers of this type are disclosed in Nishimura et al U.S. Pat. No. 4,936,998, which is incorporated herein by reference. Filter media containing these fibers are commercially sold by Asahi Medical Company. Filter media containing these fibers have demonstrated the capacity to remove leukocytes while holding down the loss of platelets.
- the filter media 28 can comprise fibers that have been surface treated as disclosed in Gsell et al. U.S. Pat. No. 5,258,127 to increase their ability to pass platelets while removing leukocytes. Gsell et al. U.S. Pat. No. 5,258,127 is also incorporated herein by reference.
- the pump 26 is used to convey PLT INI through the finishing device 24 , the external machine pressure it creates can be used to overcome passive resistance of the finishing media 28 . Therefore, the finishing media 28 can be densely packed within the finishing device 24 to achieve maximum efficiencies.
- the system 10 conveys PLT FIN to one or more containers 30 suitable for transfusion or long term storage.
- the container(s) 30 intended to store PLT FIN can be made of polyolefin material (as disclosed in Gajewski et al U.S. Pat. No. 4,140,162) or a polyvinyl chloride material plasticized with tri-2-ethylhexyl trimellitate (TEHTM). These materials, when compared to DEHP-plasticized polyvinyl chloride materials, have greater gas permeability that is beneficial for platelet storage.
- the system 10 shown in FIG. 1 can be readily incorporated into a continuous single or double needle on line blood processing systems.
- the “on line blood separation process” differs from a multiple blood bag process.
- the donor's circulatory system does not remain in communication with the flow path where separation of the collected blood volume occurs.
- the donor's circulatory system is disconnected from the primary bag before separation occurs within the bag.
- the separation processes do not occur continuously. The first stage separation of red blood cells and plasma rich in platelets and the second stage separation of platelets from plasma occur at different points in time as separate, discontiguous steps.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
Abstract
Blood processing systems and methods establish on line communication between a container and a source of blood containing leukocytes and platelets, such as a human donor. The systems and methods create a centrifugal field between the source of blood and the container that separates from the blood an unfinished suspension of platelets having a first physiologic characteristic different than the desired physiologic characteristic. The systems and methods pump the unfinished platelet suspension outside the centrifugal field through a finishing device. The finishing device changes the first physiologic characteristic to the desired physiological characteristic, thereby creating the finished platelet suspension. The systems and methods convey the finished platelet suspension from the finishing device directly into the container. The systems and methods function without interrupting the on line communication between the container and the source of blood.
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 10/024,733 filed 19 Dec. 2001, which is a division of U.S. patent application Ser. No. 09/548,190 filed 13 Apr. 2000, which is a division of U.S. patent application Ser. No. 09/223,212 filed 30 Dec. 1998, which is a division of U.S. patent application Ser. No. 08/606,189 filed 23 Feb. 1996.
- The invention generally relates to blood processing systems and methods. In a more specific sense, the invention relates to systems and methods for removing leukocytes from blood components collected for therapeutic purposes.
- Today blood collection facilities routinely separate whole blood into its various therapeutic components, such as red blood cells, platelets, and plasma.
- One separation technique that is in widespread use today uses a multiple blood bag system. The bag system includes a primary blood bag and one or more transfer bags, which are integrally connected to the primary bag by tubing. The technique collects from a donor a single unit (about 450 ml) of whole blood in the primary blood bag. The donor is then free to leave.
- The donor's whole blood later undergoes centrifugal separation within the primary bag into red blood cells and plasma rich in platelets. The plasma rich in platelets is expressed out of the primary bag into a transfer bag, leaving the red blood cells behind. The plasma rich in platelets then undergoes further centrifugal separation within the transfer bag into a concentration of platelets and plasma poor in platelets. The plasma poor in platelets is expressed from the transfer bag into another transfer bag, leaving the concentration of platelets behind.
- Using multiple blood bag systems, all three major components of whole blood can be collected for therapeutic use. However, the yield for each component collected is limited to the volume of the components that are contained in a single unit of whole blood. Furthermore, because red blood cells are retained, United States governmental regulations prohibit collecting another unit of whole blood from the donor until six weeks later.
- Certain therapies transfuse large volumes of a single blood component. For example, some patients undergoing chemotherapy require the transfusion of large numbers of platelets on a routine basis. Multiple blood bag systems simply are not an efficient way to collect these large numbers of platelets from individual donors.
- On line blood separation systems are today used to collect large numbers of platelets to meet this demand. On line systems perform the separation steps necessary to separate concentration of platelets from whole blood in a sequential process with the donor present. On line systems establish a flow of whole blood from the donor, separate out the desired platelets from the flow, and return the remaining red blood cells and plasma to the donor, all in a sequential flow loop.
- Large volumes of whole blood (for example, 2.0 liters) can be processed using an on line system. Due to the large processing volumes, large yields of concentrated platelets (for example, 4×1011 platelets suspended in 200 ml of fluid) can be collected. Moreover, since the donors red blood cells are returned, the donor can donate whole blood for on line processing much more frequently than donors for processing in multiple blood bag systems.
- Regardless of the separation technique used, when collecting blood components for transfusion, it is desirable to minimize the presence of impurities or other materials that may cause undesired side effects in the recipient. For example, because of possible febrile reactions, it is generally considered desirable to transfuse red blood cells and platelets that are substantially free of leukocytes, particularly for recipients who undergo frequent transfusions.
- Several United States patents are directed to the removal of leukocytes from red blood cells and platelet components in multiple blood bag systems. For example, see U.S. Pat. Nos. 4,767,541; 5,089,146; 5,100,564; and 5,128,048.
- U.S. Pat. No. 5,427,695 is directed to the removal of leukocytes from platelet-rich plasma during on line blood processing.
- The platelet-rich suspension product obtained using prior on line blood collection systems and methods may still lack the desired physiologic characteristics imposed by the end user (typically a blood bank or hospital) for long term storage and transfusion. For example, the platelet-rich suspension may include residual leukocytes that, while very small in relation to the leukocyte population in whole blood, are still greater than the leukocyte population standards desired by the end user.
- Therefore, despite significant advances in blood processing technology, a need still exists for further improved systems and methods for removing undesired matter like leukocytes from blood components in a way that lends itself to use in high volume, on line blood collection environments.
- The invention provides on line blood processing systems and methods for obtaining a finished platelet suspension having a desired physiologic characteristic. In a preferred embodiment, the desired physiologic characteristic comprises a desired reduced residual population of leukocytes.
- The systems and methods that embody features of the invention establish on line communication between a container and a source of blood containing leukocytes and platelets, such as a human donor. The systems and methods create a centrifugal field between the source of blood and the container. The centrifugal field separates from the blood an unfinished suspension of platelets having a first physiologic characteristic different than the desired physiologic characteristic. In a preferred embodiment, the unfinished platelet suspension contains an initial leukocyte population greater than the desired residual leukocyte population.
- According to the invention, the systems and methods pump the unfinished platelet suspension outside the centrifugal field through a finishing device. The finishing device changes the first physiologic characteristic to the desired physiological characteristic, thereby creating the finished platelet suspension. In a preferred embodiment, the finishing device reduces the leukocyte population by filtration. The systems and methods convey the finished platelet suspension from the finishing device directly into the container for storage or transfusion.
- The systems and methods that embody the features of the invention function without interrupting the on line communication between the container and the source of blood.
- Other features and advantages of the invention can be found in the drawings, accompanying description, and claims of this Specification.
-
FIG. 1 is a diagrammatic view of a blood processing system, which includes a finishing device that embodies the features of the invention; and -
FIG. 2 is a diagrammatic view of a centrifugal blood processing system that can be use in association with the finishing device shown inFIG. 1 . - The invention may be embodied in several forms without departing from its spirit or essential characteristics. The scope of the invention is defined in the appended claims, rather than in the specific description preceding them. All embodiments that fall within the meaning and range of equivalency of the claims are therefore intended to be embraced by the claims.
-
FIG. 1 shows in diagrammatic form an on lineblood processing system 10 that embodies features of the invention. According to the invention, the online system 10 provides a finished, high quality platelet-rich blood product (PLTFIN), with a significantly reduced residual population of leukocytes and/or other enhanced physiological properties, suited for long term storage and transfusion. - As used in this Specification, the term “on line blood separation process” refers to a blood separation system or method that (i) establishes communication between a blood source (typically, a human blood donor) and an extracorporeal flow path; (ii) draws a blood volume from the donor into the flow path; and (iii) maintains communication with the circulatory system of the donor for at least a portion of the time that the blood volume undergoes separation within the extracorporeal flow path.
- As used in this Specification, an “on line blood separation process” can separate the blood volume either in a continuous manner or in an interrupted manner. However, an “on line blood separation process” maintains communication between the flow path and the donor for at least a portion of the time the separation process occurs within the flow path, regardless of specific timing or sequencing of the separation process itself.
- As used in this Specification, an “on line blood separation process” can include external or internal valves or clamps to interrupt flow within the path to or from the donor. However, in the context of this Specification, such valves or claims do not break the communication between the blood donor and the flow path. Instead, the valves or clamps control fluid flow within the path while maintaining communication between it and the blood donor.
- The on
line system 10 draws whole blood (WB) from a donor through a phlebotomizedtubing flow path 12. WB contains, as its principal components, red blood cells, platelets, leukocytes, and plasma. Thesystem 10 adds anticoagulant to the drawn WB and conveys anticoagulated WB into acentrifugal field 14 for processing. - In the
centrifugal field 14, thesystem 10 ultimately separates anticoagulated WB into two components. The first component is a red blood cell concentration. It is desirable that the red blood cell concentration also carry with it a majority of the leukocyte population (LK) present in the WB. For this reason, the first component is referred to as RBCLK+. - RBCLK+ is returned to the donor during processing. This avoids depletion of the donor's red blood cell and leukocyte populations while high volume yields of platelets are obtained.
- The second component comprises an unfinished platelet-rich plasma suspension PLTUN. PLTUN is considered “unfinished” because the platelet-rich plasma suspension still lacks the desired physiologic characteristics imposed by the end user (typically a blood bank or hospital) for long term storage and transfusion. Centrifugal processing within the
field 14 often cannot provide these desired characteristics. - The specific physical makeup of the platelet-rich suspension comprising PLTUN can vary. The makeup will largely depend upon the efficiency of the centrifugal separation process in terms of the how many platelets are separated (i.e., the platelet yields) and how much platelet-poor plasma product is withdrawn and not returned to the donor.
- As used in this Specification, PLTUN is intended to encompass any suspension in which platelets are present in concentrations greater than in whole blood. PLTUN can comprise what is commonly referred to as platelet-rich plasma (PRP) or platelet concentrate (PC), or suspensions of platelets and plasma lying in between.
- PLTUN can include, in addition to platelets, other components or ingredients, depending upon the choice of the end user. For example, PLTUN can include essentially only plasma as the platelet suspension media. Alternatively or in addition to plasma, PLTUN can include a specially formulated platelet storage media to suspend the platelets.
- The structural details of the
centrifugation field 14 can vary and are not essential to the invention. For example, thefield 14 can comprise a centrifuge and multiple stage centrifugal processing chambers of the type shown in Brown U.S. Pat. No. 5,427,695 or Brown U.S. Pat. No. 5,370,802, both of which are incorporated herein by reference. - As
FIG. 2 shows in diagrammatic form, the multiple stage processing chambers that Brown '695 and '802 embody separate WB into RBC and PRP in a firststage separation chamber 16. The special fluid flow dynamics that occur in thefirst stage chamber 16 shown in Brown '802 or '695 keep a large majority of leukocytes out of PRP and with the RBC in thefirst stage chamber 16 for return to the donor as RBCLK+. The special fluid flow dynamics occurring in thefirst stage chamber 16 in Brown '802 or Brown '695 also provide a high yield of platelets in the PRP. - In Brown '802 or '695, PRP is transported from the
first stage chamber 16. A portion is recirculated back to the WB entering thefirst stage chamber 16, and the rest is conveyed into a second stage chamber 18. The PRP is separated in the second stage chamber 18 into PC and platelet-poor plasma (PPP). - PC retained in the second stage chamber 18 is later resuspended in a volume of PPP or (optionally) a suitable platelet storage medium for transfer from the second stage chamber as PLTUN. A portion of the PPP is returned to the donor, while another portion of PPP is retained for use as a recirculation or keep-open or rinse-back or resuspension media, or for storage for fractionation or transfusion.
- One reason why PLTUN can be considered “unfinished” in the context of the above described system is the presence of residual leukocytes in the platelet suspension. This residual population of leukocytes with the platelets, while small, still can be greater than the leukocyte population standards demanded by the end user.
- Often, centrifugal processing alone often is not effective at isolating enough leukocytes from PRP to meet these demands. Unintended perturbations and secondary flows along the interface between RBC and plasma, where leukocytes reside, can sweep lighter leukocyte species away from RBC into the plasma. Other desirable flow patterns that sweep heavier leukocytes species in the interface back into the RBC mass can also fail to develop to their fullest potential. The dynamic processes under which leukocytes are separated from platelets during centrifugation are complex and subject to variation from donor to donor.
- Additional steps can be provided to augment the primary centrifugal separation process to thereby reduce the number of residual leukocytes present in PLTUN. For example, as disclosed in Brown '695, a leukocyte filter 20 can be provided after the
first stage chamber 16 to filter leukocytes from PRP before entering the second stage chamber 18 for separation into PC and PPP. The filter 20 is preferably located outside thecentrifugal field 14, being connected by a rotating umbilicus arrangement 22 of conventional construction. Alternatively, though, the filter 20 can be located within thecentrifugal field 14. - Alternatively, or in combination with such other ancillary leukocyte-reduction devices, PLTUN can be subject to particle bed separation effects within the
centrifugal field 14 to separate leukocytes from the platelets. Still, the degree of leukocyte reduction demanded by the user can exceed the capabilities of even these ancillary steps during the centrifugal separation process. - For this reason (see
FIG. 1 ), thesystem 10 includes an inline finishing device 24 located outside thecentrifugal field 14. Apump 26 conveys PLTUN under pressure from thecentrifugal field 14 through the finishingdevice 24. InFIG. 1 , thepump 26 is shown downstream of thecentrifugal field 14. Alternatively, thepump 26 could be located upstream of thecentrifugal field 14, thereby supplying the requisite machine pressure to convey PLTUN from thecentrifugal field 14. - The finishing
device 24 serves to affect a desired alteration in the makeup or physiological of PLTUN that could not be effectively achieved in thecentrifugal field 14, such as, for example, a further incremental reduction in the leukocyte population. The inline finishing device 24 performs its function on line, while the donor remains connected in communication with thesystem 10. - The output of the finishing
device 24 is a finished platelet-rich suspension (PLTFIN). PLTFIN is considered “finished” because the platelet-rich plasma suspension possesses the desired physiologic characteristics imposed by the end user for long term storage and transfusion. In the context of the illustrated embodiment, the platelet-rich suspension comprising PLTFIN, possesses a more-reduced leukocyte population and/or additional physiological attributes not present in PLTINI. - As used in this Specification, the term “reduced” or “more-reduced” does not denote that all the residual leukocytes have been removed. The term is intended to more broadly indicate only that the number of residual leukocytes have been incrementally reduced by the finishing
device 24, compared with the number before processing by the finishing device. - Other physiological attributes that the finishing device can provide include (INSERT . . . . )
- The finishing
device 24 can accomplish its function by centrifugation, absorption, columns, chemical, electrical, and electromagnetic means. In the illustrated and preferred embodiment, the finishingdevice 24 comprises a filter that employs a non-woven,fibrous filter media 28. - The composition of the
filter media 28 can vary. Themedia 28 comprises fibers that contain nonionic hydrophillic groups and nitrogen-containing basic functional groups. Fibers of this type are disclosed in Nishimura et al U.S. Pat. No. 4,936,998, which is incorporated herein by reference. Filter media containing these fibers are commercially sold by Asahi Medical Company. Filter media containing these fibers have demonstrated the capacity to remove leukocytes while holding down the loss of platelets. Alternatively, thefilter media 28 can comprise fibers that have been surface treated as disclosed in Gsell et al. U.S. Pat. No. 5,258,127 to increase their ability to pass platelets while removing leukocytes. Gsell et al. U.S. Pat. No. 5,258,127 is also incorporated herein by reference. - Furthermore, because the
pump 26 is used to convey PLTINI through the finishingdevice 24, the external machine pressure it creates can be used to overcome passive resistance of the finishingmedia 28. Therefore, the finishingmedia 28 can be densely packed within the finishingdevice 24 to achieve maximum efficiencies. - The
system 10 conveys PLTFIN to one ormore containers 30 suitable for transfusion or long term storage. The container(s) 30 intended to store PLTFIN can be made of polyolefin material (as disclosed in Gajewski et al U.S. Pat. No. 4,140,162) or a polyvinyl chloride material plasticized with tri-2-ethylhexyl trimellitate (TEHTM). These materials, when compared to DEHP-plasticized polyvinyl chloride materials, have greater gas permeability that is beneficial for platelet storage. - The
system 10 shown inFIG. 1 can be readily incorporated into a continuous single or double needle on line blood processing systems. - As used in this Specification, the “on line blood separation process” differs from a multiple blood bag process. In a multiple blood bag process, the donor's circulatory system does not remain in communication with the flow path where separation of the collected blood volume occurs. In a multiple blood bag system, after a given blood volume is collected in the primary bag, the donor's circulatory system is disconnected from the primary bag before separation occurs within the bag. Also, in a multiple blood bag system, the separation processes do not occur continuously. The first stage separation of red blood cells and plasma rich in platelets and the second stage separation of platelets from plasma occur at different points in time as separate, discontiguous steps.
- Various features of the inventions are set forth in the following claims.
Claims (4)
1. (canceled)
2. An on line blood processing method for obtaining a finished concentrated blood cell suspension having a reduced residual leukocyte population
(1) establishing on line communication between a container and a source of blood having a first population of leukocytes,
(2) creating, while maintaining the on line communication between the container and the source, a centrifugal field between the source and the container that separates from the blood a first concentrated blood cell suspension and a second concentrated blood cell suspension having an initial population of leukocytes less than the first population of leukocytes and greater than the reduced residual population of leukocytes,
(3) pumping, while maintaining the on line communication between the container and the source, substantially all of the second concentrated blood cell suspension outside the centrifugal field through a finishing device outside the centrifugal field, the finishing device operating to reduce the initial leukocyte population in the second concentrated blood cell suspension, thereby creating a finished concentrated blood cell suspension having a reduced residual leukocyte population less than the initial population of leukocytes and suited for long term storage and transfusion without further processing, and
(4) conveying, while maintaining the on line communication between the container and the source, substantially all of the finished concentrated blood cell suspension from the finishing device directly into the container and not a separation device.
3. A method according to claim 2 wherein the finishing device comprises a filter media.
4. A method according to claim 2 further including providing a pump outside of the centrifugal field for pumping substantially all of the second concentrated blood cell suspension from the centrifugal field through the finishing device, and wherein the pumping is carried out by said pump.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/179,658 US20090014395A1 (en) | 1996-02-23 | 2008-07-25 | Systems and Methods for On Line Finishing of Cellular Blood Products Like Platelets Harvested for Therapeutic Purposes |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/606,189 US5865785A (en) | 1996-02-23 | 1996-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/223,212 US6051147A (en) | 1996-02-23 | 1998-12-30 | Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/548,190 US6361692B1 (en) | 1996-02-23 | 2000-04-13 | On line blood processing system for obtaining for storage a blood suspension having a reduced residual leukocyte population |
US10/024,733 US20020043492A1 (en) | 1996-02-23 | 2001-12-19 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US10/430,785 US6872307B2 (en) | 1996-02-23 | 2003-05-06 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US11/064,267 US20050139556A1 (en) | 1996-02-23 | 2005-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US12/179,658 US20090014395A1 (en) | 1996-02-23 | 2008-07-25 | Systems and Methods for On Line Finishing of Cellular Blood Products Like Platelets Harvested for Therapeutic Purposes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/064,267 Continuation US20050139556A1 (en) | 1996-02-23 | 2005-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090014395A1 true US20090014395A1 (en) | 2009-01-15 |
Family
ID=24426942
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/606,189 Expired - Lifetime US5865785A (en) | 1996-02-23 | 1996-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/223,212 Expired - Lifetime US6051147A (en) | 1996-02-23 | 1998-12-30 | Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/548,190 Expired - Lifetime US6361692B1 (en) | 1996-02-23 | 2000-04-13 | On line blood processing system for obtaining for storage a blood suspension having a reduced residual leukocyte population |
US10/024,733 Abandoned US20020043492A1 (en) | 1996-02-23 | 2001-12-19 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US10/430,785 Expired - Fee Related US6872307B2 (en) | 1996-02-23 | 2003-05-06 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US11/064,267 Abandoned US20050139556A1 (en) | 1996-02-23 | 2005-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US12/179,658 Abandoned US20090014395A1 (en) | 1996-02-23 | 2008-07-25 | Systems and Methods for On Line Finishing of Cellular Blood Products Like Platelets Harvested for Therapeutic Purposes |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/606,189 Expired - Lifetime US5865785A (en) | 1996-02-23 | 1996-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/223,212 Expired - Lifetime US6051147A (en) | 1996-02-23 | 1998-12-30 | Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US09/548,190 Expired - Lifetime US6361692B1 (en) | 1996-02-23 | 2000-04-13 | On line blood processing system for obtaining for storage a blood suspension having a reduced residual leukocyte population |
US10/024,733 Abandoned US20020043492A1 (en) | 1996-02-23 | 2001-12-19 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US10/430,785 Expired - Fee Related US6872307B2 (en) | 1996-02-23 | 2003-05-06 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US11/064,267 Abandoned US20050139556A1 (en) | 1996-02-23 | 2005-02-23 | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Country Status (13)
Country | Link |
---|---|
US (7) | US5865785A (en) |
EP (1) | EP0822845B1 (en) |
JP (1) | JPH11504350A (en) |
AR (1) | AR005954A1 (en) |
AU (1) | AU729610B2 (en) |
BR (1) | BR9702100A (en) |
CA (1) | CA2214146A1 (en) |
DE (1) | DE69736539T2 (en) |
ES (1) | ES2271965T3 (en) |
IL (1) | IL121660A (en) |
MX (1) | MX9707054A (en) |
NO (1) | NO314244B1 (en) |
WO (1) | WO1997030748A1 (en) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6053856A (en) * | 1995-04-18 | 2000-04-25 | Cobe Laboratories | Tubing set apparatus and method for separation of fluid components |
US5913768A (en) * | 1995-04-18 | 1999-06-22 | Cobe Laboratories, Inc. | Particle filter apparatus |
EP1000664B1 (en) * | 1995-04-18 | 2005-06-15 | Gambro, Inc., | Particle separation apparatus and method |
US5865785A (en) | 1996-02-23 | 1999-02-02 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US5954971A (en) * | 1997-01-07 | 1999-09-21 | Haemonetics Corporation | Pumped-filter blood-processing apparatus and methods |
US6200287B1 (en) * | 1997-09-05 | 2001-03-13 | Gambro, Inc. | Extracorporeal blood processing methods and apparatus |
US6051146A (en) * | 1998-01-20 | 2000-04-18 | Cobe Laboratories, Inc. | Methods for separation of particles |
US6669905B1 (en) | 1998-05-21 | 2003-12-30 | Baxter International Inc. | Systems and methods for collecting plasma that is free or virtually free of cellular blood species |
US6695803B1 (en) | 1998-10-16 | 2004-02-24 | Mission Medical, Inc. | Blood processing system |
US7651474B2 (en) | 1999-10-01 | 2010-01-26 | Caridianbct, Inc. | Method and apparatus for leukoreduction of red blood cells |
US6730054B2 (en) * | 1999-10-16 | 2004-05-04 | Baxter International Inc. | Blood collection systems and methods that derive estimated effects upon the donor's blood volume and hematocrit |
JP2003516175A (en) * | 1999-10-16 | 2003-05-13 | バクスター・インターナショナル・インコーポレイテッド | Automatic collection system and method for obtaining red blood cells, platelets and plasma from whole blood |
EP1946783B1 (en) * | 2000-03-09 | 2011-09-07 | CaridianBCT, Inc. | Extracorporeal blood processing apparatus |
CA2405443A1 (en) * | 2000-03-31 | 2001-10-11 | Baxter International, Inc. | Systems and methods for collecting leukocyte-reduced blood components, including plasma that is free or virtually free of cellular blood species |
US6706008B2 (en) | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
US6808503B2 (en) | 2001-03-06 | 2004-10-26 | Baxter International Inc. | Automated system and method for pre-surgical blood donation and fluid replacement |
US6884228B2 (en) | 2001-03-06 | 2005-04-26 | Baxter International Inc. | Automated system adaptable for use with different fluid circuits |
US6582386B2 (en) | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
JP4050477B2 (en) * | 2001-03-28 | 2008-02-20 | テルモ株式会社 | Blood component collection device |
WO2002087662A1 (en) * | 2001-04-27 | 2002-11-07 | Nexell Therapeutics Inc. | Cell processing and fluid transfer apparatus and method of use |
US6890291B2 (en) * | 2001-06-25 | 2005-05-10 | Mission Medical, Inc. | Integrated automatic blood collection and processing unit |
JP4512367B2 (en) | 2001-12-05 | 2010-07-28 | カリディアンビーシーティ、インコーポレイテッド | Method and apparatus for separating blood components |
ATE522237T1 (en) * | 2001-12-10 | 2011-09-15 | Caridianbct Inc | METHOD FOR REDUCING THE CONTENT OF LEUKOCYTES IN A RED BLOOD CELL COMPONENT |
US20030173274A1 (en) * | 2002-02-01 | 2003-09-18 | Frank Corbin | Blood component separation device, system, and method including filtration |
AU2003223645A1 (en) * | 2002-04-16 | 2003-11-03 | Gambro, Inc. | Blood component processing system, apparatus and method |
EP1497645A2 (en) * | 2002-04-19 | 2005-01-19 | Mission Medical, Inc. | Integrated automatic blood processing unit |
US7374678B2 (en) * | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7832566B2 (en) * | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7553413B2 (en) * | 2005-02-07 | 2009-06-30 | Hanuman Llc | Plasma concentrator device |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US20040182795A1 (en) * | 2003-03-21 | 2004-09-23 | Randel Dorian | Apparatus and method for concentration of plasma from whole blood |
US6905612B2 (en) * | 2003-03-21 | 2005-06-14 | Hanuman Llc | Plasma concentrate apparatus and method |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
DE10392686T5 (en) * | 2002-05-24 | 2005-07-07 | Biomet Mfg. Corp., Warsaw | Apparatus and method for separating and concentrating liquids containing multiple components |
US6982038B2 (en) * | 2002-06-14 | 2006-01-03 | Medtronic, Inc. | Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma |
FR2857987B1 (en) * | 2003-07-21 | 2005-10-07 | Staubli Sa Ets | FRAME OF LISSES AND WEAVING EQUIPPED WITH AT LEAST ONE SUCH FRAMEWORK |
CN2698358Y (en) * | 2004-04-06 | 2005-05-11 | 上海江夏血液技术有限公司 | Blood filtering device |
RU2284194C1 (en) * | 2005-03-29 | 2006-09-27 | Ренат Сулейманович Акчурин | Autohemotransfuser |
US20060226086A1 (en) * | 2005-04-08 | 2006-10-12 | Robinson Thomas C | Centrifuge for blood processing systems |
US7694828B2 (en) | 2005-04-27 | 2010-04-13 | Biomet Manufacturing Corp. | Method and apparatus for producing autologous clotting components |
US20070118063A1 (en) * | 2005-10-05 | 2007-05-24 | Gambro, Inc | Method and Apparatus for Leukoreduction of Red Blood Cells |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8430813B2 (en) * | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US7806276B2 (en) * | 2007-04-12 | 2010-10-05 | Hanuman, Llc | Buoy suspension fractionation system |
EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
US8337711B2 (en) * | 2008-02-29 | 2012-12-25 | Biomet Biologics, Llc | System and process for separating a material |
US8454548B2 (en) * | 2008-04-14 | 2013-06-04 | Haemonetics Corporation | System and method for plasma reduced platelet collection |
US8628489B2 (en) * | 2008-04-14 | 2014-01-14 | Haemonetics Corporation | Three-line apheresis system and method |
US8961789B2 (en) * | 2008-10-31 | 2015-02-24 | Baxter International Inc. | Systems and methods for performing hemodialysis |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8834402B2 (en) | 2009-03-12 | 2014-09-16 | Haemonetics Corporation | System and method for the re-anticoagulation of platelet rich plasma |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US9011800B2 (en) * | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
WO2012060848A1 (en) | 2010-11-05 | 2012-05-10 | Haemonetics Corporation | System and method for automated platelet wash |
US9302042B2 (en) | 2010-12-30 | 2016-04-05 | Haemonetics Corporation | System and method for collecting platelets and anticipating plasma return |
US11386993B2 (en) | 2011-05-18 | 2022-07-12 | Fenwal, Inc. | Plasma collection with remote programming |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2014127122A1 (en) | 2013-02-18 | 2014-08-21 | Terumo Bct, Inc. | System for blood separation with a separation chamber having an internal gravity valve |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9550028B2 (en) | 2014-05-06 | 2017-01-24 | Biomet Biologics, LLC. | Single step desiccating bead-in-syringe concentrating device |
US10792416B2 (en) | 2017-05-30 | 2020-10-06 | Haemonetics Corporation | System and method for collecting plasma |
US10758652B2 (en) | 2017-05-30 | 2020-09-01 | Haemonetics Corporation | System and method for collecting plasma |
US11412967B2 (en) | 2018-05-21 | 2022-08-16 | Fenwal, Inc. | Systems and methods for plasma collection |
US12033750B2 (en) | 2018-05-21 | 2024-07-09 | Fenwal, Inc. | Plasma collection |
CN112587740B (en) | 2018-05-21 | 2024-08-02 | 汾沃有限公司 | System for collecting plasma |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025618A (en) * | 1974-09-03 | 1977-05-24 | Baxter Travenol Laboratories, Inc. | Method for separation of cryoprecipitate from blook plasma |
US4680025A (en) * | 1982-08-24 | 1987-07-14 | Baxter Travenol Laboratories, Inc. | Blood component collection systems and methods |
US4701267A (en) * | 1984-03-15 | 1987-10-20 | Asahi Medical Co., Ltd. | Method for removing leukocytes |
US4915683A (en) * | 1986-11-21 | 1990-04-10 | The Medical College Of Wisconsin, Inc. | Antiviral method, agents and apparatus |
US4936998A (en) * | 1986-03-28 | 1990-06-26 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
US4985153A (en) * | 1988-06-23 | 1991-01-15 | Asahi Medical Co., Ltd. | Method for separating blood into blood components, and blood components separator unit |
US5023052A (en) * | 1988-01-20 | 1991-06-11 | Fuji Photo Film Co., Ltd. | Element for analyzing body fluids |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
US5100564A (en) * | 1990-11-06 | 1992-03-31 | Pall Corporation | Blood collection and processing system |
US5102407A (en) * | 1990-03-13 | 1992-04-07 | Miles Inc. | Blood separation system |
US5229012A (en) * | 1989-05-09 | 1993-07-20 | Pall Corporation | Method for depletion of the leucocyte content of blood and blood components |
US5236716A (en) * | 1990-02-12 | 1993-08-17 | Miles Inc. | Platelets concentrate with low white blood cells content |
US5258126A (en) * | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
US5288403A (en) * | 1992-02-28 | 1994-02-22 | Nissoh Corporation | Filter for removing leucocytes |
US5298165A (en) * | 1990-09-25 | 1994-03-29 | Asahi Medical Co., Ltd. | Method for removing leukocytes and a filter system for removing the same |
US5300019A (en) * | 1990-12-20 | 1994-04-05 | Baxter International Inc. | Systems and methods for eradicating contaminants using photoactive materials in fluids like blood |
US5387187A (en) * | 1992-12-01 | 1995-02-07 | Haemonetics Corporation | Red cell apheresis method |
US5399268A (en) * | 1989-09-12 | 1995-03-21 | Pall Corporation | Method for processing blood for human transfusion |
US5403272A (en) * | 1992-05-29 | 1995-04-04 | Baxter International Inc. | Apparatus and methods for generating leukocyte free platelet concentrate |
US5427695A (en) * | 1993-07-26 | 1995-06-27 | Baxter International Inc. | Systems and methods for on line collecting and resuspending cellular-rich blood products like platelet concentrate |
US5494592A (en) * | 1993-04-27 | 1996-02-27 | Haemonetics Corporation | Apheresis apparatus and method |
US5498336A (en) * | 1991-02-22 | 1996-03-12 | Terumo Kabushiki Kaisha | Leukocyte-removing filter and leukocyte-removing apparatus furnished therewith |
US5501795A (en) * | 1989-05-09 | 1996-03-26 | Pall Corporation | Device for depletion of the leucocyte content of blood and blood components |
US5512187A (en) * | 1991-05-08 | 1996-04-30 | Baxter International Inc. | Methods for processing red cell products for long term storage free of microorganisms |
US5536238A (en) * | 1990-12-20 | 1996-07-16 | Baxter International Inc. | Systems and methods for simultaneously removing free and entrained contaminants in fluids like blood using photoactive therapy and cellular separation techniques |
US5545516A (en) * | 1990-05-01 | 1996-08-13 | The American National Red Cross | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light |
US5545339A (en) * | 1994-02-25 | 1996-08-13 | Pall Corporation | Method for processing biological fluid and treating separated component |
US5549834A (en) * | 1991-12-23 | 1996-08-27 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
US5591337A (en) * | 1993-09-14 | 1997-01-07 | Baxter International Inc. | Apparatus for filtering leukocytes from blood cells |
US5663045A (en) * | 1993-03-24 | 1997-09-02 | Baxter International Inc. | Method for testing blood units for viral contamination |
US5690815A (en) * | 1992-07-13 | 1997-11-25 | Pall Corporation | Automated system for processing biological fluid |
US5865785A (en) * | 1996-02-23 | 1999-02-02 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140162A (en) | 1977-07-28 | 1979-02-20 | Baxter Travenol Lab | Clear, autoclavable plastic formulation free of liquid plasticizers |
US4767541A (en) | 1982-06-04 | 1988-08-30 | Miles Laboratories, Inc. | Method of removing platelets and white cells from a red cell concentrate |
US5370802A (en) | 1987-01-30 | 1994-12-06 | Baxter International Inc. | Enhanced yield platelet collection systems and methods |
US5258127A (en) | 1990-07-27 | 1993-11-02 | Pall Corporation | Leucocyte depleting filter device and method of use |
US5128048A (en) | 1991-05-22 | 1992-07-07 | Baxter International Inc. | Systems and methods for removing undesired matter from blood cells |
CA2143832A1 (en) * | 1993-07-26 | 1995-02-02 | Richard I. Brown | Systems and methods for collecting blood components |
-
1996
- 1996-02-23 US US08/606,189 patent/US5865785A/en not_active Expired - Lifetime
-
1997
- 1997-02-10 EP EP97904262A patent/EP0822845B1/en not_active Expired - Lifetime
- 1997-02-10 BR BR9702100A patent/BR9702100A/en active Search and Examination
- 1997-02-10 AU AU18589/97A patent/AU729610B2/en not_active Ceased
- 1997-02-10 DE DE69736539T patent/DE69736539T2/en not_active Expired - Lifetime
- 1997-02-10 WO PCT/US1997/001950 patent/WO1997030748A1/en active IP Right Grant
- 1997-02-10 CA CA002214146A patent/CA2214146A1/en not_active Abandoned
- 1997-02-10 MX MX9707054A patent/MX9707054A/en unknown
- 1997-02-10 ES ES97904262T patent/ES2271965T3/en not_active Expired - Lifetime
- 1997-02-10 IL IL12166097A patent/IL121660A/en not_active IP Right Cessation
- 1997-02-10 JP JP9530189A patent/JPH11504350A/en not_active Ceased
- 1997-02-21 AR ARP970100710A patent/AR005954A1/en active IP Right Grant
- 1997-10-22 NO NO19974874A patent/NO314244B1/en not_active IP Right Cessation
-
1998
- 1998-12-30 US US09/223,212 patent/US6051147A/en not_active Expired - Lifetime
-
2000
- 2000-04-13 US US09/548,190 patent/US6361692B1/en not_active Expired - Lifetime
-
2001
- 2001-12-19 US US10/024,733 patent/US20020043492A1/en not_active Abandoned
-
2003
- 2003-05-06 US US10/430,785 patent/US6872307B2/en not_active Expired - Fee Related
-
2005
- 2005-02-23 US US11/064,267 patent/US20050139556A1/en not_active Abandoned
-
2008
- 2008-07-25 US US12/179,658 patent/US20090014395A1/en not_active Abandoned
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025618A (en) * | 1974-09-03 | 1977-05-24 | Baxter Travenol Laboratories, Inc. | Method for separation of cryoprecipitate from blook plasma |
US4680025A (en) * | 1982-08-24 | 1987-07-14 | Baxter Travenol Laboratories, Inc. | Blood component collection systems and methods |
US4701267A (en) * | 1984-03-15 | 1987-10-20 | Asahi Medical Co., Ltd. | Method for removing leukocytes |
US4701267B1 (en) * | 1984-03-15 | 1996-03-12 | Asahi Medical Co | Method for removing leukocytes |
US4936998A (en) * | 1986-03-28 | 1990-06-26 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
US4915683A (en) * | 1986-11-21 | 1990-04-10 | The Medical College Of Wisconsin, Inc. | Antiviral method, agents and apparatus |
US5023052A (en) * | 1988-01-20 | 1991-06-11 | Fuji Photo Film Co., Ltd. | Element for analyzing body fluids |
US4985153A (en) * | 1988-06-23 | 1991-01-15 | Asahi Medical Co., Ltd. | Method for separating blood into blood components, and blood components separator unit |
US5501795A (en) * | 1989-05-09 | 1996-03-26 | Pall Corporation | Device for depletion of the leucocyte content of blood and blood components |
US5229012A (en) * | 1989-05-09 | 1993-07-20 | Pall Corporation | Method for depletion of the leucocyte content of blood and blood components |
US5399268A (en) * | 1989-09-12 | 1995-03-21 | Pall Corporation | Method for processing blood for human transfusion |
US5258126A (en) * | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
US5236716A (en) * | 1990-02-12 | 1993-08-17 | Miles Inc. | Platelets concentrate with low white blood cells content |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
US5102407A (en) * | 1990-03-13 | 1992-04-07 | Miles Inc. | Blood separation system |
US5545516A (en) * | 1990-05-01 | 1996-08-13 | The American National Red Cross | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light |
US5298165A (en) * | 1990-09-25 | 1994-03-29 | Asahi Medical Co., Ltd. | Method for removing leukocytes and a filter system for removing the same |
US5100564A (en) * | 1990-11-06 | 1992-03-31 | Pall Corporation | Blood collection and processing system |
US5300019A (en) * | 1990-12-20 | 1994-04-05 | Baxter International Inc. | Systems and methods for eradicating contaminants using photoactive materials in fluids like blood |
US5536238A (en) * | 1990-12-20 | 1996-07-16 | Baxter International Inc. | Systems and methods for simultaneously removing free and entrained contaminants in fluids like blood using photoactive therapy and cellular separation techniques |
US5498336A (en) * | 1991-02-22 | 1996-03-12 | Terumo Kabushiki Kaisha | Leukocyte-removing filter and leukocyte-removing apparatus furnished therewith |
US5512187A (en) * | 1991-05-08 | 1996-04-30 | Baxter International Inc. | Methods for processing red cell products for long term storage free of microorganisms |
US5549834A (en) * | 1991-12-23 | 1996-08-27 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
US5288403A (en) * | 1992-02-28 | 1994-02-22 | Nissoh Corporation | Filter for removing leucocytes |
US5403272A (en) * | 1992-05-29 | 1995-04-04 | Baxter International Inc. | Apparatus and methods for generating leukocyte free platelet concentrate |
US5690815A (en) * | 1992-07-13 | 1997-11-25 | Pall Corporation | Automated system for processing biological fluid |
US5387187A (en) * | 1992-12-01 | 1995-02-07 | Haemonetics Corporation | Red cell apheresis method |
US5663045A (en) * | 1993-03-24 | 1997-09-02 | Baxter International Inc. | Method for testing blood units for viral contamination |
US5607579A (en) * | 1993-04-27 | 1997-03-04 | Haemonetics Corporation | Apheresis apparatus for separating an intermediate density component from whole blood |
US5494592A (en) * | 1993-04-27 | 1996-02-27 | Haemonetics Corporation | Apheresis apparatus and method |
US5427695A (en) * | 1993-07-26 | 1995-06-27 | Baxter International Inc. | Systems and methods for on line collecting and resuspending cellular-rich blood products like platelet concentrate |
US5591337A (en) * | 1993-09-14 | 1997-01-07 | Baxter International Inc. | Apparatus for filtering leukocytes from blood cells |
US5545339A (en) * | 1994-02-25 | 1996-08-13 | Pall Corporation | Method for processing biological fluid and treating separated component |
US5865785A (en) * | 1996-02-23 | 1999-02-02 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US6051147A (en) * | 1996-02-23 | 2000-04-18 | Baxter International Inc. | Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US6361692B1 (en) * | 1996-02-23 | 2002-03-26 | Baxter International Inc. | On line blood processing system for obtaining for storage a blood suspension having a reduced residual leukocyte population |
US20020043492A1 (en) * | 1996-02-23 | 2002-04-18 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US6872307B2 (en) * | 1996-02-23 | 2005-03-29 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US20050139556A1 (en) * | 1996-02-23 | 2005-06-30 | Bischof Daniel F. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Also Published As
Publication number | Publication date |
---|---|
US6361692B1 (en) | 2002-03-26 |
MX9707054A (en) | 1997-12-31 |
AU729610B2 (en) | 2001-02-08 |
DE69736539T2 (en) | 2007-08-16 |
ES2271965T3 (en) | 2007-04-16 |
US6051147A (en) | 2000-04-18 |
BR9702100A (en) | 1999-07-20 |
AU1858997A (en) | 1997-09-10 |
AR005954A1 (en) | 1999-07-21 |
US20030205517A1 (en) | 2003-11-06 |
IL121660A0 (en) | 1998-02-08 |
EP0822845A1 (en) | 1998-02-11 |
NO974874L (en) | 1997-10-22 |
US6872307B2 (en) | 2005-03-29 |
US5865785A (en) | 1999-02-02 |
US20050139556A1 (en) | 2005-06-30 |
NO974874D0 (en) | 1997-10-22 |
WO1997030748A1 (en) | 1997-08-28 |
US20020043492A1 (en) | 2002-04-18 |
EP0822845B1 (en) | 2006-08-23 |
IL121660A (en) | 2001-01-11 |
CA2214146A1 (en) | 1997-08-28 |
NO314244B1 (en) | 2003-02-24 |
EP0822845A4 (en) | 1999-12-01 |
DE69736539D1 (en) | 2006-10-05 |
JPH11504350A (en) | 1999-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6872307B2 (en) | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes | |
US5549834A (en) | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes | |
EP0829267B1 (en) | Pre-storage filtration of platelets | |
US5804079A (en) | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes | |
EP0666770B1 (en) | Method for resuspending cellular-rich concentrates | |
CA1285440C (en) | Red blood cell filtering system | |
US5403272A (en) | Apparatus and methods for generating leukocyte free platelet concentrate | |
US6007725A (en) | Systems and methods for on line collection of cellular blood components that assure donor comfort | |
NL9320033A (en) | System for handling transitional area material. | |
JP2001061955A (en) | Autotransfusion device and method | |
CA2143830C (en) | Systems and methods for reducing leukocytes in cellular products | |
WO1995003112A1 (en) | Systems and methods for collecting blood components | |
JPH09168585A (en) | Blood bag system | |
CN1180318A (en) | Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes | |
van Dongen et al. | Platelets/Plasmapheresis with three Different Apheresis Machines | |
JPH09168574A (en) | Method of separating blood components | |
JPH09168575A (en) | Method of separating blood components |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |